Pablo Berlanga Charriel: The French real-world experience on chemo-immunotherapy in patients with relapsed/progressive high-risk neuroblastoma
Pablo Berlanga Charriel, Pediatric Oncology Consultant at Gustave Roussy, posted on LinkedIn:
“I am very pleased to share with you that the French real-world experience on chemo-immunotherapy in patients with relapsed/progressive high-risk neuroblastoma has been published in the European Journal of Cancer.
We show that the activity of anti-GD2 antibodies does not depend on the chemotherapy backbone. This experience underlines the importance of national collaboration to ensure adequate prospective data collection of off-label innovative anticancer.
cancer
If you want to know more about this, click on the link.
Enormous thanks to the amazing Neuroblastoma Committee of the French Society of Pediatric Oncology (SFCE), the SACHA France team, all SFCE centers and participating patients and families. Many thanks to Imagine for Margo, Association Hubert Gouin – Enfance and Cancer and Fondation du LEEM for their funding support for the SACHA- France study and to the ANSM and HAS for their precious support and collaboration.”
Source: Pablo Berlanga Charriel/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023